BTK A428D is a recurrent, pan-resistance mutation in patients with acquired resistance to BTK degraders By webmaster / June 23, 2026
BTK degradation by bexobrutideg suppresses B cell activation and FcεRI-mediated degranulation in preclinical models of chronic spontaneous urticaria By webmaster / May 14, 2026
Bexobrutideg (NX-5948), a Novel Bruton’s Tyrosine Kinase (BTK) Degrader, Shows High Clinical Activity and Tolerable Safety in Patients with Waldenström Macroglobulinemia: Updated Results from an Ongoing Phase 1a/b Study By webmaster / December 12, 2025
Bexobrutideg (NX-5948), a novel Bruton’s tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in relapsed/refractory chronic lymphocytic leukemia (CLL): New and updated findings from an ongoing Phase 1a/b trial By webmaster / December 8, 2025
Molecular and structural basis of pan-resistance to BTK targeting therapies via BTK A428D mutation By webmaster / December 6, 2025
Bexobrutideg (NX-5948), a Novel Bruton’s Tyrosine Kinase Degrader, Shows High Clinical Activity and Tolerable Safety in an Ongoing Phase 1a/b Study in Patients with Waldenström Macroglobulinemia By webmaster / September 5, 2025
Bexobrutideg (NX-5948), a Novel Bruton’s Tyrosine Kinase (BTK) Degrader, Demonstrates Rapid and Durable Clinical Responses in Relapsed/Refractory CLL: Updated Findings From an Ongoing Phase 1a Study By webmaster / September 5, 2025
Rewriting Established Drug Design Rules with a CNS-Penetrant Catalytic Bruton’s Tyrosine Kinase (BTK) Degrader By webmaster / July 22, 2025
